Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 201 - 250 out of 106,020

Document Document Title
WO/2015/070156A1
The invention relates to a rapidly disintegrating oral dosage form that contains a drug/polymer solid solution and methods of using the oral dosage form.  
WO/2015/067923A1
Prodrugs of an NMDA antagonist, (S)-1-phenyl-2-(pyridin-2-yl)ethanamine, useful for the treatment of depression (particularly major depressive disorder) or pain; compositions comprising them, and methods of making them.  
WO/2015/069110A1
The present invention relates to compounds compound according to Formula (III); and pharmaceutically acceptable salts, hydrates and solvates thereof. These compounds have D2receptor antagonist/(partial) agonist effects and H3antagonistic...  
WO/2015/067773A1
The present invention relates to an ethanol-based plant macerate which includes the following active agents obtained from plant extracts: eugenol, caffeine and/or theine, piperine, theobromine, gingerol and menthol. The ethanol-based pla...  
WO/2015/069809A1
This disclosure relates to a method of treating a neurological disorder by administering an antidepressant compound and dextromethorphan to a human being in need thereof. This method may be useful for human beings that are extensive meta...  
WO/2015/069752A9
The invention provides compositions and methods a) for increasing or stimulating the release of other transmitters (excitatory amino acids, inhibitor amino acids and biogenic amines) in the central nervous system (CNS) or the brain, or m...  
WO/2015/069833A1
Provided herein are genetic markers for predicting response to antipsychotic treatment. Genotyping of the disclosed SNPs can be used to predict response to antipsychotic drugs in patients suffering from schizophrenia. There is provided m...  
WO/2015/069086A1
A composition of the present invention containing a fraction of Panax ginseng or ginsenoside separated therefrom has an effect of activating sirtuins, and thus can be useful for medicines, cosmetics, and foods for preventing or treating ...  
WO/2015/069752A1
The invention provides compositions and methods a) for increasing or stimulating the release of other transmitters (excitatory amino acids, inhibitor amino acids and biogenic amines) in the central nervous system (CNS) or the brain, or m...  
WO/2015/070003A1
The present invention relates to the use of a pharmaceutical composition comprising a pyrethroid compound for inhibiting unwanted eye movement and for treating eye movement disorders, such as, but not limited to, nystagmus. The invention...  
WO/2015/069140A1
The invention relates to medicine and the chemical and pharmaceutical industry and concerns agents that exhibit nootropic and neuromodulatory activity. The present pharmaceutical composition in tablet form, which exhibits nootropic and n...  
WO/2015/069736A1
Enhanced methods for the generation of medial ganglionic eminence (MGE) cells from pluripotent stem cells are provided that involve an additional step of contacting the cells with an activator of FGF8 signaling while differentiating Pax6...  
WO/2015/067130A1
(S)-4-hydroxyl-2-keto-1-piracetam crystal form III (called (s)- oxiracetam crystal form III for short) has diffraction peaks at diffraction angles 2θ, wherein the diffraction angles 2θ are equal to 10.54°, 13.70°, 14.44°, 15.60°, 1...  
WO/2015/069970A1
Hybrid compounds of curcumin and melatonin as neuroprotectants are provided. The hybrid compounds are useful for the treatment and/or prevention of Alzheimer's disease (AD), as well as other neurodegenerative diseases. The hybrid compoun...  
WO/2015/069593A1
The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatmen...  
WO/2015/070034A1
Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving,...  
WO/2015/068832A1
 Provided are a composition, drug, and food for preventing, treating, and improving the symptoms of dementia. A component contained in isomerized hop extract was discovered to activate microglia. Enhancing the activation of the microgl...  
WO/2015/067782A1
The present invention relates to compound of Formula (I) or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates to the use of the compounds of Formula I as tryptophan 2,3-dioxygenase (TDO2) i...  
WO/2015/064910A1
The present invention relates to a pharmaceutical composition containing, as an active ingredient, a rice extract with high contents of antioxidant polyphenols for preventing and treating degenerative brain diseases. More specifically, e...  
WO/2015/064714A1
The present invention provides a compound that has autotaxin-inhibiting activity and is represented by formula (I) (where R1, R2, R3, R4, and R5 are as defined in the description), a drug comprising the compound as an active ingredient, ...  
WO/2015/063318A1
The present invention relates to the treatment of patients afflicted with Amyotrophic Lateral Sclerosis (ALS), wherein said patients are treated with a tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, in particular masi...  
WO/2015/065547A1
Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including immediate release dosage forms that contain a...  
WO/2015/062803A1
The present invention relates to a peptide based compound and its use in a method of prophylactic or therapeutic treatment of at least one amyloidogenic disease or use in a method of non-invasive in vivo and/or in vitro diagnosis of at l...  
WO/2015/065179A1
The present invention relates to compressed tablets for peroral delivery of the cannabinoid cannabidiol (CBD). More particularly, the invention provides a compressed tablet having a tablet weight of 60-1200 mg, said tablet being composed...  
WO/2015/066172A1
Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage f...  
WO/2015/066627A1
The present invention provides compositions and methods for modulation of neuronal networks in the CNS and/or PNS. In certain embodiments, the invention includes modulation of existing networks or restoring one or more damaged or lost ax...  
WO/2015/061856A1
The invention relates to the use of an isolated peptide of 10 to 32 amino acid residues in length for the treatment of neural injury, wherein the isolated peptide comprises at least 10 to 22 arginine residues. The peptide may be a poly-a...  
WO/2015/064764A1
Provided is an aryloyl(oxy or amino)pentafluorosulfanylbenzene compound having pharmacological action. The present invention relates to an aryloyl(oxy or amino)pentafluorosulfanylbenzene compound represented by general formula (A-I), a p...  
WO/2015/065586A1
Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including immediate release dosage forms that contain a...  
WO/2015/064842A1
The present invention relates to a pharmaceutical composition for preventing and treating blood-brain barrier disorders and central nervous system diseases containing fluoxetine and vitamin C as active ingredients. Particularly, when a l...  
WO/2015/063177A1
The invention relates to (S)-acyl-4'-phosphopantetheine derivatives, methods of their synthesis, and related medical uses of such compounds. Preferred medical uses relate to the treatment of neurodegenerative diseases, such as PKAN.  
WO/2015/064573A1
Provided are a compound represented by formula (I) or (II), a salt thereof, or solvates of the compound and salt, having an analgesic effect and high metabolic stability. Further provided are the following: an analgesic obtained from the...  
WO/2015/062391A1
The present invention provides pyrazolopyrimidone or pyrrolotriazone derivatives, method of preparing same, and pharmaceutical applications thereof. Specifically, the present invention provides pyrazolopyrimidone or pyrrolotriazone deriv...  
WO/2015/064580A1
Provided is a sulfonamide derivative represented by general formula (1) [wherein A, B, D, E, R41 and a to h are each as defined in the description], which has a highly selective α4 integrin inhibitory effect, i.e., being less effective ...  
WO/2015/066344A1
Provided are 5-HT2C receptor agonists. Also provided are methods for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Wil...  
WO/2015/066696A1
The present invention relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegene...  
WO/2015/063775A1
The present invention relates to compositions and methods for modulating autophagic cell death, particularly by regulating alpha-1- antitrypsin activity, thereby useful for treating autophagy-associated diseases. In particular, the prese...  
WO/2015/062555A1
Disclosed are a compound of formula I having higher inhibition of protein kinase G (PKG) activity and pharmaceutically acceptable salts thereof. In formula I, R1 and R2 are the same or different, each being independently chosen from the ...  
WO/2015/064447A1
 [Problem] The purpose of the invention is to provide a drug effective in the treatment and prevention of diseases and the like caused by a decrease in frataxin production. [Solution] The invention provides a frataxin enhancer containi...  
WO/2015/059697A1
The invention provides compositions comprising choline and water soluble derivatives thereof, processes for their preparation from natural sources and uses thereof.  
WO/2015/058536A1
Disclosed in the present invention is the use of a recombinant ganoderma immunomodulatory protein (rLZ-8) in preparing drugs for treating Parkinson's disease. Animal model experiments show that the recombinant ganoderma immunomodulatory ...  
WO/2015/060430A1
The purpose of the present invention is to provide a method for screening substances that participate in metabolic conversion and a kit for screening substances that participate in metabolic conversion. Said problem can be solved with mu...  
WO/2015/060333A1
Provided is a peptide characterized by having a structure, wherein a peptide that comprises an amino acid sequence represented by formula (I) is attached to the C-terminal side of a peptide that forms an α-helix, or a salt thereof: (I) ...  
WO/2015/061779A1
Methods for treating a subject in need thereof are provided which include administering a pharmaceutical composition comprising a protein transduction reagent-modified reprogramming protein to the subject, wherein the protein transductio...  
WO/2015/061328A3
The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyal...  
WO/2015/060368A1
The present invention addresses the problem of providing a compound which has a PDE2A inhibitory action and is useful as an agent for preventing or treating schizophrenia, Alzheimer's disease, etc. The present invention relates to a comp...  
WO/2015/061792A1
Compounds having the following formula (E): Formula E or a pharmaceutically acceptable salt thereof, wherein R, R', R'', X and n are as defined herein are provided. Methods comprising use of such compounds for the treatment of neurologic...  
WO/2015/059632A1
Provided herein are methods for treating a neurodegenerative disease or disor- der, or stroke using a combination of one or more RXR agonist and/or one or more Nurr1 agonist and one or more trophic factor, or pharmaceutically acceptable ...  
WO/2015/060365A1
Provided is a compound represented by formula (1), with which it is possible to perform tau imaging with a high specificity to tau, and with excellent sensitivity, while having high brain uptake, low or non-existent bone-seeking properti...  
WO/2015/060348A1
The present invention relates to a cyclic aminomethyl pyrimidine derivative and a pharmacologically acceptable salt thereof which have a highly selective action on a dopamine D4 receptor and are useful as a therapeutic agent for attentio...  

Matches 201 - 250 out of 106,020